What do we think of $OBIO
I’ve been looking for small caps where the market is pricing in very little success despite multiple catalysts lining up.
I think Orchestra BioMed ($OBIO) fits that description well and feel like Reddit is not talking about it for some odd reason.
Current price is around $4.1.
Current market cap is only ~240 M.
Why I think the market is sleeping on it:
This isn’t another biotech hoping someone notices their technology.
Medtronic licensed AVIM, is running the pivotal BACKBEAT trial, and already has a royalty agreement in place if the therapy reaches commercialization.
That’s a huge de-risking event compared with most companies at this valuation.
The FDA keeps moving things forward
Two Breakthrough Device Designations.
The FDA also reduced the pivotal trial from roughly 500 patients to 316.
Those aren’t guarantees of success, but they’re meaningful regulatory milestones.
Massive market
Hypertension affects more than 1.3 billion people globally.
Millions of those patients already receive pacemakers.
AVIM uses existing pacemakers to reduce blood pressure, meaning the commercial opportunity is significantly larger than a company with a $240M valuation would suggest.
The catalyst is close
The pivotal BACKBEAT trial is expected to complete enrollment in the coming weeks.
After that, the market’s focus shifts almost entirely toward the pivotal data expected in early 2027.
Historically, the biggest moves in biotech and medtech often occur before the data release as investors begin positioning for the catalyst.
No immediate financing overhang
Another thing I like:
The company expects to have enough cash to fund operations through the end of 2027.
That means they’re funded well beyond the expected data readout, reducing the need for near-term dilution.
Valuation
Current market cap:
~$240M
Sell-side analysts already have pre-data price targets around $11–15, despite still applying development risk.
If BACKBEAT delivers strong pivotal data and AVIM proves commercially viable, I think the market will need to revalue the company substantially.
The bull-case valuation is $40–60+ per share if the trial is successful, commercialization progresses as expected, and investors begin pricing in the long-term opportunity. That’s an optimistic scenario rather than a prediction, but it’s why I find the setup compelling. Also, this valuation only accounts for the Backbeat trial and not the other studies being under taken with other medical device giants like Terumo.
I wonder if anyone knows more/is invested? There is a huge shift towards healthcare atm that could be potential gains.